Wouter van Rheenen

Post doc and fellow in neuromuscular diseases at UMC Utrecht focusing on ALS and complex traits genetics.

[Michelle Trenkmann @MT_Genetics]

For this GWAS for lipid levels, out now in @nature, the researchers brought together a cohort of over 1.6 million individuals! The study describes many new loci for lipid levels and in-depth analyses of ancestry-specific and multi-ancestry effects
https://t.co/K9j9V5BrYA

[BNR Nieuwsradio @BNR]

Met de grootste genetische ALS-studie tot nu toe hebben onderzoekers 15 genetische risicofactoren voor de ziekte geïdentificeerd. Ook leerde het onderzoek ze meer over hoe de ziekte zich in de cellen gedraagt #wetenschapvandaag https://t.co/YzRqd1KDgM

[Veera Rajagopal  @doctorveera]

Enjoyed reading this beautiful ALS GWAS, which offers some great insights into the genetic architecture of this fatal neuro-degenerative disease.
https://t.co/FRQ4aBGm2o

[Wouter van Rheenen @wrheenen]

@doctorveera Thanks for the great summary!

[Wouter van Rheenen @wrheenen]

This has been a great collaboration, many, many thanks to all involved and all patients that participated.

[Wouter van Rheenen @wrheenen]

Really great to see our GWAS in #ALS #MND now published in @NatureGenet. A huge collaboration with researchers around the World, including ~30K ALS patients. See open access publication here: https://t.co/30ETRAuaSI.

[Wouter van Rheenen @wrheenen]

4) Co-regulatory gene networks from MetaBrain (https://t.co/Yqbbuji2iB) highlight autophagy. And 5) a role for cholesterol in ALS susceptibility, which we hypothesize could be related to impaired autophagy in ALS.

[Wouter van Rheenen @wrheenen]

@FleurryG @LSQld @WrayNaomi @PCTGenomics @MNDFoundation @NgoShyuan @Fred_Steyn Wow, huge congrats Fleur!

[Kiran Musunuru @kiranmusunuru]

A milestone in modern medicine: 1st therapeutic in vivo gene editing in human patients!

From Julian Gillmore, @intelliatweets & colleagues out today @NEJM:

https://t.co/4xyyFHAwAj

Here’s an overview of a new potential treatment for transthyretin (ATTR) amyloidosis.

(thread)

[brent richards @BrentRichards19]

A cool demonstration that the genetic determinants of Parkinson's susceptibility and progression are importantly different.

Providing exciting avenues for drug development.

https://t.co/ymkP8yza3k

[Dr Ahmad Al-Khleifat @AhmadAlKhleifat]

ALS affects 140,000 people in the world each year, but 96% of genetic studies are of European derived populations. So we made a new group in @_Makeityours to study ALS genetics risks in all populations 👉 https://t.co/XLHLKAQDup

#GlobalALSAwarenessDay #DrivingMNDResearch #MND

[GWAS_lit @GWAS_lit]

Recovery of trait heritability from whole genome sequence data https://t.co/TIAVYsV4T8

[Nicholas Ashton @NicholasAshton]

Out now @NatureComms – #plasma #NfL in >3000 people across 15 #ageing disorders.

▶️ age-based NfL levels to detect #neurodegeneration
▶️ plasma #NfL detects #dementia in #Downsyndrome, and #parkinsonian disorders and onset of #psychiatric #disorders

https://t.co/k4yDtFmqZn

[Bike Is Best @BikeIsBestHQ]

Nearly 60% of car journeys are under 5 miles. There's a better tool for the job. For short journeys #BikeIsBest

[Craig Glastonbury @C_Glastonbury]

All GWAS summary statistics should be publicly available. If you have to email / request & outline your reasons for wanting them, it's gatekeeping, and you're slowing down progress in developing drugs to combat these illnesses!

[PGC Consortium @PGCgenetics]

Latest #GWAS from the @PGCgenetics #bipolar disorder working group identifies 64 loci, 33 of them novel, using over 40k European BD cases – now published in @NatureGenet. Results could eventually aid #precision #medicine. https://t.co/Wm3E5Uf6CJ 1/7

[Aidan O’Sullivan @AidanOSulliva15]

I. Am. Not. Going. Back. To. The. Way. I. worked. Before. Covid.

No more flying 3,000 miles to give a 20 minute lecture to 15 people in a conference hotel room.

There’s a climate crisis.